LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-108 in Combination with other Anti-Cancer Agents

2025-04-16
Share:

SHANGHAI, April 16^th, 2025 – LaNova Medicines Ltd. announced that its core pipeline asset, LM-108, an anti-CCR8 mAb, has been granted to conduct a phase 2 study in combination with other anti-cancer agents.

Previous

LaNova Medicines Announces IND Approval of LM-168 by NMPA
Next

LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-302 in Combination with Anti-PD-1 Antibody